Healthmap Solutions, a kidney disease population health management company, has received $35 million in a funding round led by Guidewell and Highmark Ventures.
Using predictive analytics and clinical expertise, Healthmap works to detect kidney disease early and recommend clinically proven interventions to delay or slow disease progression. The company said its care navigation team works with patients and a full spectrum of providers (primary care, nephrologists, cardiologists, endocrinologists, and dialysis providers), to deliver personalized whole-person care.
Tampa, Fla.-based Healthmap said it would use the additional investment to fuel what it describes as explosive growth over the past couple of years, going from 60 employees in the summer of 2020 to over 500 by the end of this year. By then, Healthmap will have more than 150,000 members under contract across commercial, Medicare and Medicaid lines of business. Healthmap said it would also continue to fund research and development into initiatives that provide innovative solutions to improve chronic kidney disease (CKD).
GuideWell is the parent of Florida Blue and Triple-S Management, the Blue Cross Blue Shield plans of Florida and Puerto Rico, while Highmark and its Blue-branded affiliates cover members in Pennsylvania, Delaware, West Virginia, and New York. Both are customers of Healthmap.
Eric Reimer, Healthmap CEO, explained that health plans and health systems across the country are searching for a kidney solution partner because of the massive size and scale of the problem, which has been accelerated in recent years by the federal CURES Act and the “Advancing American Kidney Health Initiative” Executive Order.
In a statement, Highmark Health’s chief financial officer, Saurabh Tripathi, said, “This partnership draws on natural synergies between Highmark and Healthmap, as we are both committed to revolutionizing healthcare delivery in the U.S. Our goal is to improve kidney care and reduce costs with new approaches to care. We are excited to work with Healthmap’s proprietary artificial intelligence to build individualized care plans at scale and partner with our network providers to enable them to be more effective and efficient in caring for these complex patients.”
Previous investors Windrose, DCHP, Shulman Ventures, and management also participated in the funding round.
